NCT00169533View on ClinicalTrials.gov

Rollover Study Of Lapatinib In Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 19, 2004

Primary Completion Date

May 5, 2009

Study Completion Date

May 5, 2009

Conditions
Neoplasms, Breast
Interventions
DRUG

GW572016 oral tablets

Lapatinib either at 750, 1000, 1250 or 1500 mgs

Trial Locations (12)

19111

GSK Investigational Site, Philadelphia

27599

GSK Investigational Site, Chapel Hill

27705

GSK Investigational Site, Durham

37203

GSK Investigational Site, Nashville

44106

GSK Investigational Site, Cleveland

46202

GSK Investigational Site, Indianapolis

48201

GSK Investigational Site, Detroit

64239

GSK Investigational Site, Tel Aviv

78229

GSK Investigational Site, San Antonio

87131

GSK Investigational Site, Albuquerque

03756

GSK Investigational Site, Lebanon

T6G 1Z2

GSK Investigational Site, Edmonton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY